Login to Your Account



Poniard Hardly Alone

Endpoint Hit, Stock Walloped: Street, Media Miss the Point?

By Randy Osborne


Monday, February 1, 2010
Last week, Wall Street slammed Poniard Pharmaceuticals Inc. after the company disclosed apparently good news: an endpoint met in the Phase II trial with picoplatin in metastatic colorectal cancer. It was anything but the first time that the wider world reflexively failed - at least from the company's point of view - to understand and appreciate study data.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription